US Stocks Movement: Eli Lilly Soars on September 24th as Onswik Approval and Collaboration with InnoCare Pharma Announced

Eli Lilly September 24 Surge Explained

Keywords: Onswik Approval, InnoCare Pharma Cooperation

1. On September 24, Eli Lilly announced that the US FDA approved Onswik to be used alongside diet and exercise to control high blood sugar in adults with type 2 diabetes. This drug is a once-weekly basal insulin, which means more than 300 fewer injections per year compared to once-daily basal insulin. The QWINT phase 3 trial involved over 3,400 patients.

2. On September 24, Eli Lilly and InnoCare Pharma reached a strategic research cooperation and licensing agreement. InnoCare Pharma will use its proprietary drug discovery platform to develop up to five innovative target programs. Eli Lilly will pay up to $100 million in upfront and near-term payments, about $3.25 billion in R&D and commercial milestone payments, and pay tiered single-digit royalties based on product sales.

3. On September 21, Eli Lilly's CEO stated that since Medicare launched coverage for obesity drugs in July, 700,000 new elderly patients have started using GLP-1 drugs, of whom about 70% are using Eli Lilly products. Eligible beneficiaries in the related Bridge program pay $50 per month out-of-pocket.

(Disclaimer: This content is collected and summarized from public information by AI technology and is for reference only. It does not constitute investment advice.)